Obesity Medicine

The greatest risk for developing cancer faces residents of South Dakota, where radon levels are the nation's highest, and ranks for alcohol consumption and obesity are poor.

Overweight individuals in the highest dose group with weight loss at day 28 continued to lose weight at the 2-week follow-up, with metabolic changes mimicking ketogenic effects.

Posing an unparalleled threat of premature disease and death globally, the unchecked rise in overweight and obesity requires an urgent 5-year action plan, experts say.

Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.

In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.

Weekly subcutaneous injections of amycretin featured a safety profile similar to other incretin-based drugs, according to new topline results.

Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.

The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.

Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.

Your daily dose of the clinical news you may have missed.

Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

Your daily dose of the clinical news you may have missed.

"Twincretin" tirzepatide-treated participants in SURMOUNT-5 lost a mean 50 lbs vs an average loss of 33 lbs for those treated with semaglutide.

In a study of adults enrolled in a telehealth weight management program, 45% decreased their alcohol use after taking antiobesity medication.

With the recent surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.